BioSpace15h
Lilly Signs Back-to-Back Deals in MASH, Cancer
Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...
The Motley Fool9d
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
We could point out that tirzepatide, the active ingredient in Mounjaro and Zepbound, is still undergoing many clinical trials ...
MarketWatch4d
Lilly’s Mounjaro and Zepbound contribute to big revenue boost, drugmaker says
Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...
Yahoo Finance5d
Zepbound sales keep soaring, even as weight loss drug growth slows
Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth ... The company’s stock rose just over 2% during morning trading on Thursday. Despite impressive sales ...
Morningstar5d
Lilly's Mounjaro and Zepbound contribute to big revenue boost, drugmaker says
GLP-1 drugs Mounjaro and Zepbound drive a big revenue increase for the drugmaker Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound ...
AOL9d
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro ... delayed the onset of type 2 diabetes in patients with ...